LIGAND PHARMACEUTICALS INC - FORM 10-K - EX-10.106 - FIRST AMENDMENT TO LICENSE AGREEMENT - March 3, 2011

Attached files

file filename
10-K - FORM 10-K - LIGAND PHARMACEUTICALS INCd10k.htm
EX-31.1 - CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER - LIGAND PHARMACEUTICALS INCdex311.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - LIGAND PHARMACEUTICALS INCdex231.htm
EX-31.2 - CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER - LIGAND PHARMACEUTICALS INCdex312.htm
EX-21.1 - SUBSIDIARIES OF REGISTRANT - LIGAND PHARMACEUTICALS INCdex211.htm
EX-32.1 - CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER - LIGAND PHARMACEUTICALS INCdex321.htm
EX-32.2 - CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER - LIGAND PHARMACEUTICALS INCdex322.htm
EX-10.107 - SECOND AMENDMENT TO LICENSE AGREEMENT - LIGAND PHARMACEUTICALS INCdex10107.htm
EX-10.105 - LICENSE AGREEMENT - LIGAND PHARMACEUTICALS INCdex10105.htm
EX-10.114 - SUPPLY AGREEMENT - LIGAND PHARMACEUTICALS INCdex10114.htm
EX-10.109 - NONEXCLUSIVE LICENSE AGREEMENT - LIGAND PHARMACEUTICALS INCdex10109.htm
EX-10.113 - AMENDMENT TO LICENSE AGREEMENT - LIGAND PHARMACEUTICALS INCdex10113.htm
EX-10.100 - CAPTISOL SUPPLY AGREEMENT - LIGAND PHARMACEUTICALS INCdex10100.htm
EX-10.103 - 3RD AMENDMENT TO CAPTISOL SUPPLY AGREEMENT - LIGAND PHARMACEUTICALS INCdex10103.htm
EX-10.101 - 1ST AMENDMENT TO CAPTISOL SUPPLY AGREEMENT - LIGAND PHARMACEUTICALS INCdex10101.htm
EX-10.102 - 2ND AMENDMENT TO CAPTISOL SUPPLY AGREEMENT - LIGAND PHARMACEUTICALS INCdex10102.htm
EX-10.104 - 4TH AMENDMENT TO CAPTISOL SUPPLY AGREEMENT - LIGAND PHARMACEUTICALS INCdex10104.htm
EX-10.111 - ACKNOWLEDGEMENT AGREEMENT - LIGAND PHARMACEUTICALS INCdex10111.htm
EX-10.112 - LICENSE AGREEMENT - LIGAND PHARMACEUTICALS INCdex10112.htm
EX-10.108 - EXCLUSIVE LICENSE AGREEMENT - LIGAND PHARMACEUTICALS INCdex10108.htm
EX-10.110 - ADDENDUM TO NONEXCLUSIVE LICENSE AGREEMENT - LIGAND PHARMACEUTICALS INCdex10110.htm

Exhibit 10.106

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

LOGO

 

February 24, 1998

Ms. Victoria Thomas

General Counsel

University of Kansas

245 Strong Hall

Lawrence, KS 66045

Dear Ms. Thomas:

The letter shall serve as an amendment to the license agreement between CyDex, Inc. and the University of Kansas dated September 3, 1993.

Section 7.1(c) is modified as follows:

(c) [***]; and

New Section 7.1(e) added:

(e) [***].

The above two amendments shall be effective upon execution by their duly authorized representatives.

 

UNIVERSITY OF KANSAS     CyDex, Inc.
By:  

/s/ [Illegible]

     By:  

/s/ [Illegible]

Title:  

Associate Vice Chancellor

     Title:  

Vice President Corporate Development

Date:  

February 25, 1998

     Date:  

Feb. 24, 1998

 

 

*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

Stock widget

Investing forum

LIGAND PHARMACEUTICALS INC Reports

Also read